43. Kongress der Deutschen Gesellschaft für Rheumatologie, 29. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie, 25. Wissenschaftliche Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie
02.-05. September 2015, Bremen
Poster
Posterwalk „Rheumatoide Arthritis I“
Meeting Abstract
(RA.37)
[Full Text]
Inzidenz der Manifestation einer rheumatoiden Arthritis bei Patienten mit Arthralgien und positivem CCP-Antikörpernachweis: Pilotstudie zur Wirksamkeit von Hydroxychloroquin
Köhler L, Jablonka A, Schmidt RE, Merkesdal S[Full Text]
Meeting Abstract
(RA.09)
[Full Text]
In Children With Systemic Juvenile Idiopathic Arthritis With And Without Fever Canakinumab is Long Term Safe and Efficacious
Horneff G, Ruperto N, Brunner H, Quartier P, Constantin T, Alexeeva E, Kone-Paut I, Marzan K, Wulffraat N, Schneider R, Padeh S, Chasnyk V, Wouters C, Kümmerle-Deschner J, Kallinich T, Lauwerys BR, Haddad E, Nasonov E, Trachana M, Vougiouka O, Abrams K, Leon K, Lheritier K, Martini A, Lovell DJ[Full Text]
Meeting Abstract
(RA.10)
[Full Text]
Plasticity of classic and non-classic Th1 cells towards a Th17 phenotype in RA
Klose A, Pirronello F, Skapenko A, Schulze-Koops H, Leipe J[Full Text]
Meeting Abstract
(RA.11)
[Full Text]
Beta-Confident Registry Results Show Long-Term Safety And Efficacy Of Canakinumab in Cryopyrin-Associated Periodic Syndrome (CAPS) Patients
Kümmerle-Deschner J, Hoffman HM, Hawkins PN, van der Poll T, Walker UA, Speziale A, Tilson H[Full Text]
Meeting Abstract
(RA.12)
[Full Text]
Diagnostische Wertigkeit des Prednisolontests bei Patienten mit möglicher rheumatoider Arthrits
Kiltz U, von Zabern C, Baraliakos X, Heldmann F, Mintrop B, Sarholz M, van Werde M, Klink C, Krause DMJ, Dybowski F, Kalthoff L, Hein L, Braun J[Full Text]
Meeting Abstract
(RA.13)
[Full Text]
Conjoint Methodology Used to Assess Patient preferences in Cryopyrin-associated autoinflammatory syndrome (CAPS)
Kümmerle-Deschner J, Krause K, Kortus-Götze B, Thürigen A, Pisa G[Full Text]
Meeting Abstract
(RA.14)
[Full Text]
C-EARLY, eine randomisierte, doppelblinde, kontrollierte Phase-3 Studie mit Certolizumab Pegol plus Methotrexat bei DMARD-naiven Patienten mit früher rheumatoider Arthritis führte zu anhaltendem klinischen Ansprechen und radiologischer Inhibition
Emery P, Bingham CO 3rd, Burmester GR, Bykerk V, Furst D, Mariette X, van der Heijde D, Tatla D, Arendt C, Mountian I, VanLunen B, Weinblatt ME[Full Text]
Meeting Abstract
(RA.15)
[Full Text]
Pharmacokinetics of Canakinumab treated CAPS Children younger than 2 Years old
Kümmerle-Deschner J, Kalabus J, Brogan P, Hofer M, Lauwerys BR, Speziale A, Laxer R, Sun H, Abrams K, Leon K, Junge G[Full Text]
Meeting Abstract
(RA.16)
[Full Text]
Prospektive und retrospektive Sicherheitsberichte zum Ausgang von Schwangerschaften unter CERTOLIZUMAB PEGOL
Clowse M, Förger F, Cush J, Wolf D, Golembesyki A, Shaughnessy L, De Cuyper D, Mahadevan U[Full Text]
Meeting Abstract
(RA.17)
[Full Text]
On Drug and Drug-Free Remission by Baseline Disease Duration in the AVERT Trial: Abatacept versus Methotrexate Comparison in Patients with Early Rheumatoid Arthritis
Bykerk V, Burmester GR, Combe B, Furst D, Huizinga T, Wong D, Emery P[Full Text]
Meeting Abstract
(RA.18)
[Full Text]
Effect of Anti-Cyclic Citrullinated Peptide 2 Immunoglobulin M Serostatus on Efficacy Outcomes Following Treatment with Abatacept Plus Methotrexate in the AVERT Trial
Huizinga T, Connolly SE, Johnsen A, Zhu J, Furst D, Bykerk V, Burmester GR, Combe B, Wong D, Trouw L, Toes R, Emery P[Full Text]
Meeting Abstract
(RA.19)
[Full Text]
Depression und Angststörungen bei Patienten mit einer Früharthritis
Freier D, Höhne-Zimmer V, Ducks D, Klaus P, Braun T, Köhler V, Burmester GR, Detert J[Full Text]
Meeting Abstract
(RA.20)
[Full Text]
Einsparpotential von Glucocorticoiden unter Tocilizumab i.v.-Therapie bei Rheumatoider Arthritis (RA) mit und ohne csDMARDs
Specker C, Kaufmann J, Kästner P, Kellner H, Schwarze I, Sieburg M, Vollmer MA, Körber H, Hofmann MW, Flacke JP, Fliedner G[Full Text]
Meeting Abstract
(RA.21)
[Full Text]
Bestimmung der anti-Drug-Antikörper bei Patienten mit rheumatoider Arthritis unter einer Langzeit-Therapie mit Etanercept
Drynda S, Kekow J[Full Text]
Meeting Abstract
(RA.22)
[Full Text]
Do Changes in Clinical Practice over Time in Europe and Canada Have an Impact on Baseline Characteristics of Patients Initiating Intravenous Abatacept in the ACTION Study?
Nüßlein HG, Alten RHE, Galeazzi M, Lorenz HM, Cantagrel A, Chartier M, Poncet C, Rauch C, Le Bars M[Full Text]
Meeting Abstract
(RA.23)
[Full Text]
Increases in Serum Cholesterol with Baricitinib Treatment are Associated with Favorable Changes in Apolipoprotein Content and with Improvement in DAS28-CRP in Patients with Rheumatoid Arthritis
Kremer JM, Genovese MC, Keystone E, Taylor P, Zuckerman SH, Schlichting D, Nantz E, Beattie S, Macias W, Holzkämper T[Full Text]
Meeting Abstract
(RA.24)
[Full Text]
Incidence Rates of Skin Cancers During Exposure to Intravenous and Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: Results from Pooled Clinical Trial Data
Simon T, Poncet C, Hochberg MC, Boers M[Full Text]
Meeting Abstract
(RA.25)
[Full Text]
Optimierung der Umrechnungsformel von FFbH- in HAQ-Werte
Huscher D, Specker C, Fliedner G, Albrecht K, Bischoff S, Thiele K, Krause A, Schuch F, Alten RHE, Zink A[Full Text]
Meeting Abstract
(RA.32)
[Full Text]
Retention Rates and Clinical Outcomes in Cohorts of Patients (Biologic Naïve or Failed Prior Biologics) Treated with Intravenous Abatacept in a Real-World Setting: 6-Month Results from the ACTION Study
Alten RHE, Nüßlein HG, Galeazzi M, Lorenz HM, Mariette X, Cantagrel A, Chartier M, Poncet C, Rauch C, Le Bars M[Full Text]